journal article
Open Access
Jan 21, 2025
Menopausal Hormone Therapy: Its Role in the Prevention of Cardiovascular Diseases and the Risk of Breast Cancer in Women
Abstract
Objective: This review was conducted to explain how menopausal hormone therapy (MHT) benefits cardiovascular diseases (CVDs) and how to control the risk of breast cancer. Mechanism: Estrogen deficiency, altered energy homeostasis, adipocyte changes, inflammation, and insulin resistance are responsible for the development of metabolic syndrome and CVDs. Estrogen influences hypothalamic function and maintains the energy balance, protecting menopausal women from these cardiovascular risk factors. However, estrogen metabolism plays a crucial role in the genotoxic pathway that leads to breast cancer. Moreover, MHT is associated with cell proliferation and mutation signaling pathways in breast cancer, as well as the process of growing the breast cancer stem cell. Findings in Brief: While MHT may have favorable effects when started early, introducing it later in the course of atherosclerosis may pose major dangers, underlining the importance of timing in hormone therapy. Estrogen-only therapy has a greater favorable effect on CVDs than the estrogen-progesterone combination. Although the connection between MHT and breast cancer is well-documented, significant knowledge gaps remain, especially regarding the long-term effects of newer MHT formulations. Current studies support using the lowest effective dose for the shortest possible duration, with a focus on tailoring therapy to individual risk factors, such as obesity, smoking, and alcohol consumption. Thus, MHT should be customized due to the intricacy of individual risk factors and differences in responses to therapy. Conclusions: Although MHT is effective for controlling CVDs in women entering menopause, it must be used with caution, especially in women at high risk of breast cancer.
Topics
No keywords indexed for this article. Browse by subject →
References
125
[1]
Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, et al. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Medicine. 2021; 18: e1003731.
10.1371/journal.pmed.1003731.
[2]
Genazzani AR. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2002; 105: e71.
10.1161/01.cir.0000012248.01291.cf
[3]
da Silva JS, Montagnoli TL, de Sá MPL, Zapata-Sudo G. Heart Failure in Menopause: Treatment and New Approaches. International Journal of Molecular Sciences. 2022; 23: 15140.
10.3390/ijms232315140.
[4]
Lethaby A, Suckling J, Barlow D, Farquhar CM, Jepson RG, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. The Cochrane Database of Systematic Reviews. 2004; CD000402.
10.1002/14651858.cd000402.pub2.
[5]
Anagnostis P, Lambrinoudaki I, Stevenson JC, Goulis DG. Menopause-associated risk of cardiovascular disease. Endocrine Connections. 2022; 11: e210537.
10.1530/ec-21-0537.
[6]
Tempfer CB, Hilal Z, Kern P, Juhasz-Boess I, Rezniczek GA. Menopausal Hormone Therapy and Risk of Endometrial Cancer: A Systematic Review. Cancers. 2020; 12: 2195.
10.3390/cancers12082195.
[7]
Mair KM, Gaw R, MacLean MR. Obesity, estrogens and adipose tissue dysfunction - implications for pulmonary arterial hypertension. Pulmonary Circulation. 2020; 10: 2045894020952019.
10.1177/2045894020952023.
[8]
Maas AHEM. Hormone therapy and cardiovascular disease: Benefits and harms. Best Practice & Research. Clinical Endocrinology & Metabolism. 2021; 35: 101576.
10.1016/j.beem.2021.101576.
[9]
Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer Journal (Sudbury, Mass.). 2022; 28: 208–223.
10.1097/ppo.0000000000000591.
[10]
Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023; 147: 597–610.
10.1161/circulationaha.122.061559.
[11]
Deng Y, Jin H. Effects of menopausal hormone therapy-based on the role of estrogens, progestogens, and their metabolites in proliferation of breast cancer cells. Cancer Biology & Medicine. 2021; 19: j.issn.2095–3941.2021.0344.
10.20892/j.issn.2095-3941.2021.0344.
[12]
Bak MJ, Das Gupta S, Wahler J, Suh N. Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. Seminars in Cancer Biology. 2016; 40-41: 170–191.
10.1016/j.semcancer.2016.03.001.
[13]
Naftolin F, Friedenthal J, Nachtigall R, Nachtigall L. Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment. F1000Research. 2019; 8: F1000 Faculty Rev–1576.
10.12688/f1000research.15548.1.
[14]
Boardman HMP, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. The Cochrane Database of Systematic Reviews. 2015; 2015: CD002229.
10.1002/14651858.cd002229.pub4.
[15]
Mehta J, Kling JM, Manson JE. Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts. Frontiers in Endocrinology. 2021; 12: 564781.
10.3389/fendo.2021.564781.
[16]
Kim JE, Chang JH, Jeong MJ, Choi J, Park J, Baek C, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Scientific Reports. 2020; 10: 20631.
10.1038/s41598-020-77534-9.
[17]
Mahmoodzadeh S, Dworatzek E. The Role of 17β-Estradiol and Estrogen Receptors in Regulation of Ca2+ Channels and Mitochondrial Function in Cardiomyocytes. Frontiers in Endocrinology. 2019; 10: 310.
10.3389/fendo.2019.00310.
[18]
Oliver-Williams C, Glisic M, Shahzad S, Brown E, Pellegrino Baena C, Chadni M, et al. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Human Reproduction Update. 2019; 25: 257–271.
10.1093/humupd/dmy039.
[19]
Topçuoglu A, Uzun H, Aydin S, Kahraman N, Vehid S, Zeybek G, et al. The effect of hormone replacement therapy on oxidized low density lipoprotein levels and paraoxonase activity in postmenopausal women. The Tohoku Journal of Experimental Medicine. 2005; 205: 79–86.
10.1620/tjem.205.79.
[20]
Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Therapeutic Advances in Cardiovascular Disease. 2017; 11: 215–225.
10.1177/1753944717711379.
[21]
McMenamin Ú, Hicks B, Hughes C, Murchie P, Hippisley-Cox J, Ranger T, et al. Hormone replacement therapy in women with cancer and risk of cancer-specific mortality and cardiovascular disease: a protocol for a cohort study from Scotland and Wales. BMC Cancer. 2021; 21: 313.
10.1186/s12885-021-08065-3.
[22]
Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, et al. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020; 75: 2602–2618.
10.1016/j.jacc.2020.03.060.
[23]
Chopra S, Sharma KA, Ranjan P, Malhotra A, Vikram NK, Kumari A. Weight Management Module for Perimenopausal Women: A Practical Guide for Gynecologists. Journal of Mid-life Health. 2019; 10: 165–172.
10.4103/jmh.jmh_155_19.
[24]
Ha KH, Kim DJ. Association of metabolic syndrome with coronary artery calcification. The Korean Journal of Internal Medicine. 2015; 30: 29–31.
10.3904/kjim.2015.30.1.29.
[25]
Vigil P, Meléndez J, Petkovic G, Del Río JP. The importance of estradiol for body weight regulation in women. Frontiers in Endocrinology. 2022; 13: 951186.
10.3389/fendo.2022.951186.
[26]
Gusev E, Sarapultsev A. Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes. International Journal of Molecular Sciences. 2023; 24: 7910.
10.3390/ijms24097910.
[27]
du Cailar G, Ribstein J, Pasquié JL, Mimran A. Determinant of left ventricular hypertrophy in the hypertensive woman. Influence of hormone replacement therapy for menopause. Archives des Maladies du Coeur et des Vaisseaux. 1999; 92: 975–977.
[28]
Ko SH, Jung Y. Energy Metabolism Changes and Dysregulated Lipid Metabolism in Postmenopausal Women. Nutrients. 2021; 13: 4556.
10.3390/nu13124556.
[29]
Giovannelli P, Di Donato M, Galasso G, Di Zazzo E, Medici N, Bilancio A, et al. Breast cancer stem cells: The role of sex steroid receptors. World Journal of Stem Cells. 2019; 11: 594–603.
10.4252/wjsc.v11.i9.594.
[30]
Ganesan K, Du B, Chen J. Effects and mechanisms of dietary bioactive compounds on breast cancer prevention. Pharmacological Research. 2022; 178: 105974.
10.1016/j.phrs.2021.105974.
[31]
Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. The New England Journal of Medicine. 2016; 374: 1221–1231.
10.1056/nejmoa1505241.
[32]
Sriprasert I, Hodis HN, Karim R, Stanczyk FZ, Shoupe D, Henderson VW, et al. Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause. The Journal of Clinical Endocrinology and Metabolism. 2019; 104: 293–300.
10.1210/jc.2018-01600.
[33]
Gotto AM, Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. Journal of the American College of Cardiology. 2004; 43: 717–724.
10.1016/j.jacc.2003.08.061.
[34]
Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation. 2016; 133: 1073–1080.
10.1161/circulationaha.115.019014.
[35]
Hale GE, Shufelt CL. Hormone therapy in menopause: An update on cardiovascular disease considerations. Trends in Cardiovascular Medicine. 2015; 25: 540–549.
10.1016/j.tcm.2015.01.008.
[36]
Christian CA, Moenter SM. The neurobiology of preovulatory and estradiol-induced gonadotropin-releasing hormone surges. Endocrine Reviews. 2010; 31: 544–577.
10.1210/er.2009-0023.
[37]
Riaz NN, Rehman F, Ahmad MM. β-Amino Acids: Role in Human Biology and Medicinal Chemistry - A Review. Medicinal Chemistry. 2017; 7: 302–307.
10.4172/2161-0444.1000472
[38]
Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science (New York, N.Y.). 2005; 308: 1583–1587.
10.1126/science.1112062.
[39]
Swica Y, Warren MP, Manson JE, Aragaki AK, Bassuk SS, Shimbo D, et al. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women’s Health Initiative hormone therapy trials. Menopause (New York, N.Y.). 2018; 25: 753–761.
10.1097/gme.0000000000001067.
[40]
Carrasquilla GD. Postmenopausal hormone therapy and cardiovascular risk [Doctoral Thesis]. Karolinska Institutet: Sweden. 2018.
[41]
Alsiraj Y, Woolley C, Thatcher S, Cassis L. Chapter 11 - Sex Differences and the Role of the Renin-Angiotensin System in Atherosclerosis and Abdominal Aortic Aneurysms. Sex Differences in Cardiovascular Physiology and Pathophysiology (pp. 167–184). Academic Press: Cambridge, Massachusetts, USA. 2019.
10.1016/b978-0-12-813197-8.00011-7.
[42]
Yoh K, Ikeda K, Horie K, Inoue S. Roles of Estrogen, Estrogen Receptors, and Estrogen-Related Receptors in Skeletal Muscle: Regulation of Mitochondrial Function. International Journal of Molecular Sciences. 2023; 24: 1853.
10.3390/ijms24031853.
[43]
Bai J, Qi QR, Li Y, Day R, Makhoul J, Magness RR, et al. Estrogen Receptors and Estrogen-Induced Uterine Vasodilation in Pregnancy. International Journal of Molecular Sciences. 2020; 21: 4349.
10.3390/ijms21124349.
[44]
Sun Y, Wang Y, Fan C, Gao P, Wang X, Wei G, et al. Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Molecular Cancer. 2014; 13: 137.
10.1186/1476-4598-13-137.
[45]
Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine. 2015; 175: 531–539.
10.1001/jamainternmed.2014.8063.
[46]
Panay N, Ang SB, Cheshire R, Goldstein SR, Maki P, Nappi RE, et al. Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper. Climacteric: the Journal of the International Menopause Society. 2024; 27: 441–457.
10.1080/13697137.2024.2394950.
[47]
Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. Journal of the American College of Cardiology. 2004; 44: 1593–1600.
10.1016/j.jacc.2004.07.040.
[48]
Santen RJ. The oestrogen paradox: a hypothesis. Endokrynologia Polska. 2007; 58: 222–227.
[49]
Nie G, Yang X, Wang Y, Liang W, Li X, Luo Q, et al. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022; 13: 850815.
10.3389/fphar.2022.850815.
[50]
Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric. 2010; 13: 429–432.
10.3109/13697137.2010.507111.
Showing 50 of 125 references
Metrics
3
Citations
125
References
Details
- Published
- Jan 21, 2025
- Vol/Issue
- 52(1)
- License
- View
Authors
Cite This Article
Tam Thai Thanh Tran, Thu Minh Phung, Anh Thi Mai Do, et al. (2025). Menopausal Hormone Therapy: Its Role in the Prevention of Cardiovascular Diseases and the Risk of Breast Cancer in Women. Clinical and Experimental Obstetrics & Gynecology, 52(1). https://doi.org/10.31083/ceog26813
Related
You May Also Like
Troponin I and D-Dimer levels in preeclampsia and eclampsia: prospective study
M. Bozkurt, A.E. Yumru · 2015
20 citations
Postpartum Haemorrhage Risk Prediction Model Developed by Machine Learning Algorithms: A Single-Centre Retrospective Analysis of Clinical Data
Wenhuan Wang, Chanchan Liao · 2024
10 citations
The effects of overweight and obesity on pregnancy-related morbidity
Amanda M. Wang, Alan J. Lee · 2021
7 citations
Miscarriage perceptions and experiences among Saudi women
A. A. Rouzi, R. Alamoudi · 2020
5 citations
Preoperative factors affecting the intraoperative core body temperature in elective hysterectomy under general anesthesia
E. Chalari, G. Intas · 2019
4 citations